Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

MiniMed Group, Inc. MMED

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.1B
▲ 14.3% YoY
$-333.0M
$-420.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

MiniMed Group, Inc. develops, manufactures and markets solutions for the management of diabetes. As of April 2026, its employee base consisted of approximately 8,000 people globally, including a technical workforce of approximately 15% in innovation and research and development. In fiscal year 2026, it generated $3.1 billion in revenue, of which approximately 82% came from sales of CGMs, other consumables, software and services. Its corporate headquarters is in Northridge, California. It operates two main manufacturing facilities, in California and Puerto Rico. MiniMed was founded by Alfred E. Mann in the early 1980s with the introduction of the MiniMed 502 insulin pump.

Written from the business description in MiniMed Group, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.

Growth

USD 3.1B
Revenue, FY2025 · full 3-year series below
Revenue $B Net income $B
FY2025 · Revenue 3.1 · Net income -0.3
2B3B
202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−10 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.1% · Net -10.2%
-5%-10%
202320242025
ROE
FY2025 · ROE -9.6%
-5%
202320242025
Three returns, three denominators.

Each USD of equity lost 10 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -420.0
-150M-300M
202320242025

Total assetsUSD 4.6B
EquityUSD 3.6B
CashUSD 298.0M
Current ratio1.92×

Equity funds 78% of total assets.

The 3-year record

3 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
MMED, 3-year financial record
Metric 202520242023
Revenue $B3.12.72.5
Operating income $B−0.2−0.1−0.1
EBITDA $B−0.0−0.00.1
Income tax $B0.10.10.0
Net income $B−0.3−0.2−0.1
Free cash flow $B−0.4−0.1−0.1
EPS, diluted $−1.30−0.84−0.44
Dividend / sh $◌◌◌
Payout % — not applicable: no dividend———
ROE %−9.6−6.3−3.2
Shares out B0.280.000.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 13 reconciliationsAUDITED

Reconciled in 3 of the 3 fiscal years we could check. 34 checks were skipped: the balance sheet is not tagged before 2024. 16 checks were skipped: EPS is not tagged before 2023. 16 checks were skipped: revenue is not tagged before 2023.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2023

Share this section

Download image